AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended dose of the combination of AVE8062
with platinum salts (cisplatin or carboplatin) and taxanes (docetaxel or paclitaxel) in
patients with advanced solid tumors for which platinum-taxane doublet constitutes mainstay of
care.